Last update 08 May 2025

SHR-2173

Overview

Basic Info

Drug Type
Biological products
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
Immune System DiseasesSkin and Musculoskeletal DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Systemic Lupus ErythematosusLupus NephritisPurpura, Thrombocytopenic, Idiopathic+ [1]
Inactive Indication-
Originator Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.
Active Organization
Guangdong Hengrui Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with SHR-2173
NCT06955598
/ RecruitingPhase 1
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
CTR20244025
/ RecruitingPhase 1
在系统性红斑狼疮患者中评估多次皮下注射SHR-2173注射液的安全性、耐受性、药代动力学和药效学的I期临床研究
[Translation] A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 Injection in Patients with Systemic Lupus Erythematosus
CTR20241431
/ CompletedPhase 1
健康受试者单次皮下注射SHR-2173注射液的安全性、耐受性、药代动力学和药效学I期临床研究
[Translation] A Phase I clinical study on the safety, tolerability, pharmacokinetics and pharmacodynamics of a single subcutaneous injection of SHR-2173 injection in healthy subjects
100 Clinical Results associated with SHR-2173
Login to view more data
100 Translational Medicine associated with SHR-2173
Login to view more data
100 Patents (Medical) associated with SHR-2173
Login to view more data
100 Deals associated with SHR-2173
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 1
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
28 Apr 2024
Lupus NephritisIND Approval
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
13 Dec 2024
Purpura, Thrombocytopenic, IdiopathicIND Approval
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
29 Oct 2024
Glomerulonephritis, IGAIND Approval
China
Guangdong Hengrui Pharmaceutical Co., Ltd.
28 Apr 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free